WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013055996) TREATMENT OF PHARMACOLOGICAL-INDUCED HYPOCHLORHYDRIA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/055996    International Application No.:    PCT/US2012/059875
Publication Date: 18.04.2013 International Filing Date: 12.10.2012
IPC:
A61K 31/198 (2006.01), A61K 31/205 (2006.01), A61K 31/4439 (2006.01), A61K 31/519 (2006.01), A61K 31/00 (2006.01), A61P 1/00 (2006.01)
Applicants: GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco, California 94080 (US).
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street 12th Floor Oakland, California 94607 (US)
Inventors: BENET, Leslie Z.; (US).
DALZIEL, Gena; (US).
DEAN, Brian; (US).
DRESSER, Mark; (US).
FRYMOYER, Adam; (US).
HOLDEN, Scott; (US).
JIN, Jin; (US).
WARE, Joseph A.; (US)
Agent: ANDRUS, Alex; Genentech, Inc. 1 DNA Way, MS-49 South San Francisco, California 94080 (US)
Priority Data:
61/546,814 13.10.2011 US
Title (EN) TREATMENT OF PHARMACOLOGICAL-INDUCED HYPOCHLORHYDRIA
(FR) TRAITEMENT DE L'HYPOCHLORHYDRIE INDUITE PHARMACOLOGIQUEMENT
Abstract: front page image
(EN)Changes in gastric pH due to oral co-administration of acid-reducing agents, such as proton pump inhibitors, and oncology drugs can have a marked impact on the absorption and oral bioavailability of the oncology drug if the pH decreases the maximal absorbable dose. Moreover, there is a potential for specific drug-drug interactions between some of the acid-reducing agents and these drugs. Methods are described for treating patients on gastric acid-reducing therapy with orally-administered PI3K inhibitor compound GDC-0941. Treatment with a re-acidification compound during treatment with GDC-0941 improves bioavailability of GDC-0941.
(FR)Des changements du pH gastrique dus à l'administration conjointe, par voie orale, d'agents réduisant l'acidité, tels que des inhibiteurs de la pompe à protons, et de médicaments oncologiques peuvent avoir un effet important sur l'absorption et la biodisponibilité orale du médicament oncologique si le pH diminue la dose maximale absorbable. De plus, des interactions médicament-médicament spécifiques sont possibles entre certains des agents réduisant l'acidité et ces médicaments. L'invention concerne des méthodes de traitement de patients suivant une thérapie destinée à réduire l'acidité gastrique, au moyen du composé GDC-0941 inhibant PI3K administré par voie orale. Un traitement utilisant un composé de réacidification pendant le traitement par GDC-0941 permet d'améliorer la biodisponibilité de GDC-0941.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)